Literature DB >> 17329324

Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells.

Michael S Bennett1, Hwee L Ng, Mirabelle Dagarag, Ayub Ali, Otto O Yang.   

Abstract

Cytotoxic T lymphocytes (CTLs) are crucial for immune control of viral infections. "Functional avidity," defined by the sensitizing dose of exogenously added epitope yielding half-maximal CTL triggering against uninfected target cells (SD(50)), has been utilized extensively as a measure of antiviral efficiency. However, CTLs recognize infected cells via endogenously produced epitopes, and the relationship of SD(50) to antiviral activity has never been directly revealed. We elucidate this relationship by comparing CTL killing of cells infected with panels of epitope-variant viruses to the corresponding SD(50) for the variant epitopes. This reveals a steeply sigmoid relationship between avidity and infected cell killing, with avidity thresholds (defined as the SD(50) required for CTL to achieve 50% efficiency of infected cell killing [KE(50)]), below which infected cell killing rapidly drops to none and above which killing efficiency rapidly plateaus. Three CTL clones recognizing the same viral epitope show the same KE(50) despite differential recognition of individual epitope variants, while CTLs recognizing another epitope show a 10-fold-higher KE(50), demonstrating epitope dependence of KE(50). Finally, the ability of CTLs to suppress viral replication depends on the same threshold KE(50). Thus, defining KE(50) values is required to interpret the significance of functional avidity measurements and predict CTL efficacy against virus-infected cells in pathogenesis and vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329324      PMCID: PMC1900201          DOI: 10.1128/JVI.02362-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.

Authors:  D Nelson; C Bundell; B Robinson
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

Review 2.  Will we be able to 'spot' an effective HIV-1 vaccine?

Authors:  Otto O Yang
Journal:  Trends Immunol       Date:  2003-02       Impact factor: 16.687

3.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

5.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

Authors:  David H O'Connor; Todd M Allen; Thorsten U Vogel; Peicheng Jing; Ivan P DeSouza; Elizabeth Dodds; Edward J Dunphy; Cheri Melsaether; Bianca Mothé; Hiroshi Yamamoto; Helen Horton; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

6.  Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients.

Authors:  Katsuhiko Fukada; Hiroko Tomiyama; Chantapong Wasi; Tomoko Matsuda; Shigeru Kusagawa; Hironori Sato; Shinichi Oka; Yutaka Takebe; Masafumi Takiguchi
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

7.  Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.

Authors:  W M Cohen; A Bianco; F Connan; L Camoin; M Dalod; G Lauvau; E Ferriès; B Culmann-Penciolelli; P M van Endert; J P Briand; J Choppin; J G Guillet
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.

Authors:  Ayub Ali; Rachel Lubong; Hwee Ng; David G Brooks; Jerome A Zack; Otto O Yang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses.

Authors:  Ayub Ali; Beth D Jamieson; Otto O Yang
Journal:  J Virol Methods       Date:  2003-06-30       Impact factor: 2.014

10.  Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes.

Authors:  Otto O Yang; Phuong Thi Nguyen Sarkis; Ayub Ali; Jason D Harlow; Christian Brander; Spyros A Kalams; Bruce D Walker
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more
  42 in total

1.  Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.

Authors:  Brenda De Keersmaecker; Sabine D Allard; Patrick Lacor; Rik Schots; Kris Thielemans; Joeri L Aerts
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

2.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

3.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences.

Authors:  Laura E Valentine; Shari M Piaskowski; Eva G Rakasz; Nathan L Henry; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

5.  Retracing our STEP towards a successful CTL-based HIV-1 vaccine.

Authors:  Otto O Yang
Journal:  Vaccine       Date:  2008-02-27       Impact factor: 3.641

6.  Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes.

Authors:  Diana Y Chen; Arumugam Balamurugan; Hwee L Ng; William G Cumberland; Otto O Yang
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

7.  Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein.

Authors:  Jonah B Sacha; Matthew R Reynolds; Matthew B Buechler; Chungwon Chung; Anna K Jonas; Lyle T Wallace; Andrea M Weiler; Wonhee Lee; Shari M Piaskowski; Taeko Soma; Thomas C Friedrich; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

8.  Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.

Authors:  Lara Vojnov; Jason S Reed; Kim L Weisgrau; Eva G Rakasz; John T Loffredo; Shari M Piaskowski; Jonah B Sacha; Holly L Kolar; Nancy A Wilson; R Paul Johnson; David I Watkins
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Dynamic regulation of functionally distinct virus-specific T cells.

Authors:  Zaza M Ndhlovu; Mathias Oelke; Jonathan P Schneck; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

10.  Immunodominant HIV-1-specific HLA-B- and HLA-C-restricted CD8+ T cells do not differ in polyfunctionality.

Authors:  Nompumelelo Mkhwanazi; Christina F Thobakgale; Mary van der Stok; Shabashini Reddy; Zenele Mncube; Fundisiwe Chonco; Bruce D Walker; Marcus Altfeld; Philip J R Goulder; Thumbi Ndung'u
Journal:  Virology       Date:  2010-07-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.